ArticleJournal of autism and developmental disorders2022
Autism Tsunami: the Impact of Rising Prevalence on the Societal Cost of Autism in the United States.
Article in Journal of autism and developmental disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Retractions of Health Economic Evaluations: A Systematic Review.PharmacoEconomics - open · 2026Pooled it
- The Impact of Autism Spectrum Disorder on Parents in Arab Countries: A Systematic Literature Review.Frontiers in psychology · 2022Pooled it
- Stepped Transition to Employment and Postsecondary Education Success (STEPS) for Adolescents and Adults with Autism: Community Implementation Pilot Trial.JMIR formative research · 2025Article
- The association between intolerance of uncertainty and psychological burden among caregivers of children with autism and the impact on their quality of life.Frontiers in psychiatry · 2025Article
- The Apprentice Model 2.0: Enhancement of the Apprentice Model.Behavior analysis in practice · 2023Review
- The Ethics of Actually Helping People: Targeting Skill Acquisition Goals That Promote Meaningful Outcomes for Individuals with Autism Spectrum Disorder.Behavior analysis in practice · 2023Review
- Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder.Psychedelic medicine (New Rochelle, N.Y.) · 2023Review
- Are sleep disturbances a cause or consequence of autism spectrum disorder?Psychiatry and clinical neurosciences · 2023Article
- Article
- Fidelity to the ACT SMART Toolkit: an instrumental case study of implementation strategy fidelity.Implementation science communications · 2023Article
- Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States.Journal of managed care & specialty pharmacy · 2023Observational
- Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology.Translational psychiatry · 2023Review
- Anti-ableism and scientific accuracy in autism research: a false dichotomy.Frontiers in psychiatry · 2023Article
- The Role of Intraamygdaloid Oxytocin and D2 Dopamine Receptors in Reinforcement in the Valproate-Induced Autism Rat Model.Biomedicines · 2022Article
- Effects of Soy-Based Infant Formula on Weight Gain and Neurodevelopment in an Autism Mouse Model.Cells · 2022Article
- Urinary metabolomics using gas chromatography-mass spectrometry: potential biomarkers for autism spectrum disorder.BMC neurology · 2022Article
- Promotion and implementation effectiveness of World Health Organization's Caregiver Skills Training program in Taiwan.Frontiers in psychiatry · 2022Article
- Precision Autism: Genomic Stratification of Disorders Making Up the Broad Spectrum May Demystify Its "Epidemic Rates".Journal of personalized medicine · 2021Article
Corrections and comments
- Retraction · 2023-06-05Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Conflict of Interest · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cost of ASD in the U.S. is estimated using a forecast model that for the first time accounts for the true historical increase in ASD. Model inputs include ASD prevalence, census population projections, six cost categories, ten age brackets, inflation projections, and three future prevalence scenarios. Future ASD costs increase dramatically: total base-case costs of $223 (175-271) billion/year are estimated in 2020; $589 billion/year in 2030, $1.36 trillion/year in 2040, and $5.54 (4.29-6.78) trillion/year by 2060, with substantial potential savings through ASD prevention. Rising prevalence, the shift from child to adult-dominated costs, the transfer of costs from parents onto government, and the soaring total costs raise pressing policy questions and demand an urgent focus on prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.